The Outcome of Haplo-Identical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report

Despite tremendous strides in the treatment of multiple myeloma (MM), the disease remains incurable and is defined by multiple series of responses and relapses. In the relapsed/refractory setting, outcomes for patients may be particularly discouraging. Moreover, patients with adverse cytogenetics and other high-risk features may experience particularly short progression-free survival (PFS) and inferior survival rates.[1]
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research